---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-014619"
form_type: "8-K"
ticker: "ALBT"
cik: "0001630212"
company_name: "Avalon GloboCare Corp."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:35:05.879352+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology

## Summary
- Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.
- Patent covers bispecific anti-CD19xCD22 CAR design and localized cytokine induction to enhance CAR cell cytotoxicity, survival, and proliferation.
- Technology aims to improve expansion, manufacturing, and efficacy of CAR-T and CAR-NK cells for cancer treatment.
- Extends Avalon's global IP footprint to China, supplementing existing U.S. and PCT protections.
- CEO David Jin highlights potential for practical, cost-effective point-of-care cancer solutions.

## SEC filing metadata
- accession: 0001213900-25-014619
- form_type: 8-K
- ticker: ALBT
- cik: 0001630212
- company_name: Avalon GloboCare Corp.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/0001213900-25-014619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/ea0231383-8k_avalon.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-014619
- JSON: https://secwatch.observer/filing/0001213900-25-014619.json
- Plain text: https://secwatch.observer/filing/0001213900-25-014619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.